Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

749
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
749
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Env-pseudoviruses based on the HIV-1 genetic variant circulating in Siberia.

Vavilovskii zhurnal genetiki i selektsii·2025
Same author

Use of Adjuvant Compositions Based on Squalene Ensures Induction of Neutralizing Antibodies against SARS-CoV-2.

Bulletin of experimental biology and medicine·2024
Same author

Construction and Characterization of HIV-1 env-Pseudoviruses of the Recombinant Form CRF63_02A and Subtype A6.

Bulletin of experimental biology and medicine·2022
Same author

Concentration of viruses and electron microscopy.

Vavilovskii zhurnal genetiki i selektsii·2021
Same author

Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy.

Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry·2020
Same author

[Development of drugs on the basis of high-polymeric double-stranded RNA for antiviral and antitumor therapy].

Biomeditsinskaia khimiia·2019

Related Experiment Video

Updated: Mar 30, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

[An antitumor osteotropic agent based on tumor necrosis factor].

L R Lebedev1, E D Danilenko1, Yu V Telegina1

  • 1Institute of Medical Biotechnology, State Research Center of Virology and Biotechnology "Vector", Berdsk, Russia.

Biomeditsinskaia Khimiia
|November 6, 2015
PubMed
Summary

A new drug combines tumor necrosis factor (TNF-alpha) and bisphosphonate to target bone metastases. This novel structure enhances drug delivery and antitumor activity for bone cancer treatment.

Keywords:
alendronic acidnanoparticlestumor necrosis factor

More Related Videos

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

6.4K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.7K

Related Experiment Videos

Last Updated: Mar 30, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

6.4K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.7K

Area of Science:

  • Biomaterials Science
  • Drug Delivery
  • Oncology

Background:

  • Bone metastases represent a significant challenge in cancer treatment.
  • Current therapies often lack targeted delivery to bone tissue.
  • Tumor necrosis factor-alpha (TNF-alpha) and double-stranded ribonucleic acid (dsRNA) exhibit antitumor properties.

Purpose of the Study:

  • To design and synthesize a novel drug conjugate for targeted bone metastases treatment.
  • To combine antitumor agents with a bone-targeting moiety.
  • To characterize the physicochemical properties and bone-affinity of the designed drug.

Main Methods:

  • Synthesis of dextran conjugates with TNF-alpha and alendronic acid.
  • Self-assembly of molecular structures and separation via gel filtration (Sepharose CL-6B).
  • Characterization using electrophoresis, transmission electron microscopy, and sorption/desorption assays.

Main Results:

  • Successful synthesis of TNF-alpha and alendronic acid conjugates with dextran.
  • Formation of self-assembled drug structures with particle sizes of 30-40 nm.
  • Demonstrated enhanced affinity of TNF-alpha conjugates to hydroxyapatite compared to native TNF-alpha.

Conclusions:

  • A novel drug conjugate effectively targets bone tissue through bisphosphonate's affinity for hydroxyapatite.
  • The designed molecular structure integrates antitumor activity with targeted delivery for bone metastases.
  • This approach holds promise for improved therapeutic strategies against bone metastases.